Electronic supplementary material ESM Downloadable slide (download PPTX (PPTX 145 kb) Rights and permissions Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made
Thereafter, we verify your insurance information
A Phase 2 RCT published in NEJM 2023 reported a mean body weight reduction of approximately 24% at 48 weeks with the 12 mg weekly dose in adults with obesity
iGF-1 LR3 - 0.1mg Filled with inert gas or in a vacuum White Crystalline Solid
Baseline Patient Characteristics Patient characteristics captured from the administrative claims data during the 12-month baseline period included age, gender, insurance type, geographic region, Charlson comorbidity index [21, 22] and commonly diagnosed comorbid conditions operationalized by the Agency for Healthcare Research and Quality [23]
Continued treatment with Tirzepatide for maintenance of weight reduction in adults with obesity
